Trial intelligence / Profile preview

Phase 3 trial of oral azacitidine versus placebo with best supportive care in low-risk transfusion-dependent myelodysplastic syndromes

MOH_2017-05-01_000366Phase 3Recruiting

Sponsor

Celgene Corporation

Start

Feb 2013

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules

Countries

1